Glycomet SR: Advanced Sustained-Release Metformin for Optimal Glycemic Control
| Product dosage: 500mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 180 | $0.21 | $36.98 (0%) | 🛒 Add to cart |
| 270 | $0.18 | $55.47 $49.02 (12%) | 🛒 Add to cart |
| 360 | $0.17
Best per pill | $73.96 $61.06 (17%) | 🛒 Add to cart |
Similar products
Glycomet SR is a sustained-release formulation of metformin hydrochloride, designed to provide consistent and prolonged glycemic management in patients with type 2 diabetes. As a cornerstone of oral antidiabetic therapy, it works primarily by decreasing hepatic glucose production and improving insulin sensitivity in peripheral tissues. Its unique extended-release mechanism ensures stable plasma concentrations, reducing peak-trough fluctuations and enhancing patient adherence through once-daily dosing. This formulation is particularly suited for individuals requiring long-term metabolic control with minimized gastrointestinal side effects.
Features
- Contains metformin hydrochloride 500 mg or 1000 mg in a sustained-release matrix
- Utilizes a hydrophilic polymer-based delivery system for gradual drug release
- Designed for once-daily oral administration
- Bioequivalent to immediate-release metformin in terms of total exposure
- Manufactured under strict pharmaceutical quality control standards
- Available in blister packs with clear dosage identification
Benefits
- Provides 24-hour glycemic control with single daily dosing
- Demonstrates reduced incidence of gastrointestinal adverse effects compared to immediate-release formulations
- Lowers fasting and postprandial blood glucose levels effectively
- Improves HbA1c by approximately 1-2% in most patients
- May contribute to modest weight stabilization or loss in overweight patients
- Offers convenient dosing schedule enhancing long-term treatment adherence
Common use
Glycomet SR is primarily indicated as monotherapy or in combination with other antidiabetic agents for the management of type 2 diabetes mellitus in adults. It is particularly appropriate for patients who experience gastrointestinal intolerance with immediate-release metformin formulations. The medication may also be used off-label for polycystic ovary syndrome (PCOS) management under specialist supervision, and as part of comprehensive metabolic syndrome treatment protocols.
Dosage and direction
The recommended starting dose is 500 mg once daily with the evening meal. Dosage may be increased by 500 mg weekly based on glycemic response, up to a maximum of 2000 mg daily. The total daily dose should be taken once daily with the evening meal to maximize efficacy and minimize gastrointestinal discomfort. Tablets must be swallowed whole and never crushed, chewed, or divided. Renal function should be assessed before initiation and periodically during treatment, with dosage adjustment required for patients with eGFR below 45 mL/min/1.73m².
Precautions
- Assess renal function before initiation and at least annually during treatment
- Temporarily discontinue before radiographic procedures involving intravascular iodinated contrast materials
- Monitor vitamin B12 levels periodically, especially in patients with anemia or peripheral neuropathy
- Use with caution in elderly patients due to potential decreased renal function
- Avoid excessive alcohol intake due to increased risk of lactic acidosis
- Consider temporary discontinuation during conditions predisposing to dehydration or hypoxemia
Contraindications
- Severe renal impairment (eGFR below 30 mL/min/1.73m²)
- Known hypersensitivity to metformin or any excipients
- Acute or chronic metabolic acidosis, including diabetic ketoacidosis
- Severe hepatic impairment
- Acute conditions that may alter renal function (dehydration, severe infection, shock)
- History of lactic acidosis with metformin or other biguanides
Possible side effects
- Gastrointestinal disturbances (nausea, vomiting, diarrhea, abdominal discomfort) - typically transient
- Metallic taste sensation
- Decreased vitamin B12 absorption with possible deficiency
- Lactic acidosis (rare but serious)
- Hypoglycemia (particularly when used with other antidiabetic agents)
- Skin reactions including urticaria and erythema
Drug interaction
- Cationic drugs (amiloride, digoxin, morphine, procainamide, quinidine, quinine, ranitidine, triamterene, trimethoprim, vancomycin) may increase metformin concentration
- Alcohol potentiates metformin’s effect on lactate metabolism
- Glucocorticoids, diuretics, and sympathomimetics may reduce hypoglycemic effect
- Enhanced hypoglycemic effect with insulin, sulfonylureas, and other antidiabetic agents
- Possible interaction with iodinated contrast media requiring temporary discontinuation
Missed dose
If a dose is missed, take it as soon as remembered unless it is nearly time for the next scheduled dose. Do not double the dose to make up for a missed dose. Resume the regular dosing schedule with the next dose. Consistent daily administration is important for optimal glycemic control, but occasional missed doses are unlikely to significantly affect overall metabolic control.
Overdose
Metformin overdose, particularly in the presence of contraindications, may lead to lactic acidosis characterized by elevated blood lactate levels, electrolyte disturbances, and metabolic acidosis. Symptoms include vomiting, abdominal pain, muscle pain, dizziness, and impaired consciousness. Hypoglycemia has not been reported with metformin monotherapy overdose. Management includes immediate discontinuation, supportive measures, and hemodialysis if necessary, as metformin is dialyzable.
Storage
Store at room temperature (15-30°C) in original packaging, protected from moisture and light. Keep blister strips sealed until time of administration. Do not store in bathrooms or other areas with high humidity. Keep out of reach of children and pets. Do not use beyond the expiration date printed on the packaging.
Disclaimer
This information is provided for educational purposes only and does not constitute medical advice. Individual patient requirements may vary based on clinical circumstances. Always consult a qualified healthcare professional before initiating or modifying any treatment regimen. The prescribing physician should be consulted for specific dosage recommendations and monitoring parameters based on individual patient characteristics.
Reviews
Clinical studies demonstrate Glycomet SR’s efficacy in maintaining glycemic control with improved gastrointestinal tolerability profile. A 24-week multicenter trial showed 78% of patients achieved HbA1c <7% with once-daily dosing. Patient satisfaction surveys indicate preference for the sustained-release formulation due to reduced dosing frequency and decreased side effects. Long-term observational studies confirm maintained efficacy over 52 weeks of treatment with consistent safety profile.